REG - RTW Venture Fund Ltd - March Factsheet & First Quarter Letter

RTW Biotech OpportunitiesAnnouncement

24/04/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230424:nRSX2631Xa&default-theme=true

RNS Number : 2631X  RTW Venture Fund Limited  24 April 2023

LEI: 549300Q7EXQQH6KF7Z84

24 April 2023

RTW Venture Fund Limited

March Factsheet & First Quarter Letter

-2.7% NAV Return for the Quarter Ended 31 March 2023

RTW Venture Fund Limited (the "Company"), the London Stock Exchange Premium
Listed investment fund focused on identifying transformative assets with high
growth potential across the biopharmaceutical and medical technology sectors
is pleased to announce that the March Factsheet and First Quarter 2023 Letter
are available on the Company's website
(https://www.rtwfunds.com/rtw-venture-fund-ltd/fact-sheets/) .

Developments in the quarter:

§ The Russell 2000 Biotech Index (-8.0%) and the Nasdaq Biotech Index (-2.1%)
fell over the quarter despite significant M&A in the sector.

§ Cincor was acquired by AstraZeneca for a total deal value of $1.8bn, a 206%
premium to the prior closing value.

§ Orchestra BioMed merged with RTW's Health Sciences Acquisitions Corporation
and started trading on Nasdaq.

§ Mineralys went public through an upsized IPO and traded well on debut.

§ The Company co-led private financing rounds in two cell therapy companies:
Orciell Therapeutics and Cargo Therapeutics.

§ Milestone announced a $125m strategic financing deal with RTW-managed funds
include the Company

§ Avidity announced that discussions with the FDA were ongoing regarding the
partial clinical hold of it Phase 1/2 clinical trial for AOC1001.

§ After the quarter end, Prometheus Biosciences, the Company's largest
position was acquired by Merck for $10.8bn, a 75% premium to the prior closing
value.

 

For Further Information:

 RTW Investments, LP                               +44 (0)20 7959 6361
 Woody Stileman, Managing Director

 Krisha McCune, Director, Client Service

 Buchanan                                          +44 (0)20 7466 5107
 Charles Ryland
 Henry Wilson
 George Beale

 Numis                                             +44 (0)20 7260 1000
 Freddie Barnfield
 Nathan Brown
 Euan Brown

 BofA Securities                                   +44 (0) 20 7628 1000
 Edward Peel
 Kieran Millar

 Elysium Fund Management Limited                   +44 (0) 14 8181 0100
 Joanna Duquemin Nicolle, Chief Executive Officer
 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC              +1 (914) 225 8885

 

 About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused
on identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Venture Fund invests in
companies developing next-generation therapies and technologies that can
significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a
leading healthcare-focused entrepreneurial investment firm with deep
scientific expertise and a strong track record of supporting companies
developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com
(https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF)  for more
information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUQGCUPWGWC